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AbstrACt
Objective Young people moving from child and adolescent 
mental health services (CAMHS) to adult mental health 
services (AMHS) are faced with significant challenges. 
To improve this state of affairs, there needs to be a 
recognition of the problem and initiatives and an urgent 
requirement for appropriate tools for measuring readiness 
and outcomes at the transfer boundary (16–18 years of 
age in Europe). The objective of this study was to develop 
and validate the Transition Readiness and Appropriateness 
Measure (TRAM) for assessing a young person’s readiness 
for transition, and their outcomes at the transfer boundary.
Design MILESTONE prospective study.
setting Eight European Union (EU) countries participating 
in the EU- funded MILESTONE study.
Participants The first phase (MILESTONE validation 
study) involved 100 adolescents (pre- transition), young 
adults (post- transition), parents/carers and both CAMHS 
and AMHS clinicians. The second phase (MILESTONE 
cohort study and nested cluster randomised trial) involved 
over 1000 young people.
results The development of the TRAM began with a 
literature review on transitioning and a review of important 
items regarding transition by a panel of 34 mental health 
experts. A list of 64 items of potential importance were 
identified, which together comprised the TRAM. The 
psychometric properties of the different versions of the 
TRAM were evaluated and showed that the TRAM had 
good reliability for all versions and low- to- moderate 
correlations when compared with other established 
instruments and a well- defined factor structure. The 
main results of the cohort study with the nested cluster 
randomised trial are not reported.
strengths and limitations of this study
 ► The European Union- funded Managing the Link and 
Strengthening Transition from Child to Adult Mental 
Healthcare in Europe (MILESTONE) study provides a 
useful model to evaluate the readiness of transition 
for young people.
 ► The MILESTONE study allowed the Transition 
Readiness and Appropriateness Measure (TRAM) to 
be holistic in its scope because it ensured that all the 
essential information to assist with transition from 
child and adolescent mental health services to adult 
mental health services was captured in its entirety, 
especially given the fact that the transition journey 
for young people is very difficult and often poorly 
managed.
 ► The focus groups gathered extensive input from 
young people, their family members and mental 
health professionals with experience in transition 
within mental health.
 ► The web- based aspect of the TRAM allowed it to be 
completed remotely using developmentally appro-
priate interfaces, which aided in its completion.
 ► Transition is not static and further evaluation of the 
TRAM is warranted in young people to assess tran-
sition readiness longitudinally.
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Conclusion The TRAM is a reliable instrument for assessing transition 
readiness and appropriateness. It highlighted the barriers to a successful 
transition and informed clinicians, identifying areas which clinicians on 
both sides of the transfer boundary can work on to ease the transition for 
the young person.
trial registration number ISRCTN83240263 (Registered 23 July 2015), 
NCT03013595 (Registered 6 January 2017); Pre- results.
IntrODuCtIOn
Ensuring a smooth transition process from paediatric 
to adult healthcare services has been a significant chal-
lenge for healthcare providers in recent years. Young 
people with chronic somatic conditions usually undergo 
a review when they reach the service transfer boundary1; 
however, in the mental healthcare setting an assessment 
of transition readiness and appropriateness of young 
people to transfer has not been well developed. Tran-
sition in mental health services refers to the process of 
young people moving from child and adolescent mental 
health services (CAMHS) to adult mental health services 
(AMHS—specialist adult teams and community- based 
services),2 the boundary being the age at which they can 
no longer access care from CAMHS (16–18 years of age in 
Europe). Among countries in the European Union (EU), 
only Denmark and the UK have guidelines detailing how 
the process should be managed, and only 40% of member 
states have facilities for transition planning.3 Despite this, 
transition transfer across the CAMHS- AMHS boundary 
has received less research attention than transitions in 
other healthcare settings, such as for young people with 
chronic conditions4–7 or special healthcare needs.8
Transition in the mental health setting requires a 
multidimensional approach that covers a young person’s 
psychosocial, educational and vocational needs. Various 
assessments of improving transition outcomes have been 
developed.9–16 Some explore the readiness for transi-
tion, such as treatment engagement, medication use and 
housing,10 while others have focused specifically on the 
readiness for transition12 or assessing the quality of inter-
action in service user/practitioner relationships.13 The 
current evidence base does not suggest that one measure 
of transition might be more efficacious than another, 
however, in the mental healthcare setting it seems that 
certain components might be more useful than others. 
Some of the core components have been described and 
encompass measures that include the readiness, plan-
ning, transfer of care and transfer of completion.17 The 
Transitions of Care from Child and Adolescent Mental 
Health Services to Adult Mental Health Services (TRACK) 
study18 19 noted that youth reaching the CAMHS transition 
boundary have variable outcomes, including inadequate 
transition procedures and disengagement from services. 
These factors can have a significant health economic 
impact on young people and their families.20 Others have 
shown that transition should be both personalised and 
flexible, and crucially incorporate the perspectives of 
young people.21
A mapping survey of 28 EU countries showed that the 
characteristics of CAMHS to AMHS transition services 
varies in terms of distribution of services, funding and 
user access.22 This implies that not enough resources and 
funds have been allocated to prevent discontinuity of care 
at the transfer boundary and that disengagement from 
services may be a significant problem across the conti-
nent. Furthermore, while new national and international 
initiatives are clearly warranted, tools to inform decision- 
making at the transfer boundary and to enable reliable 
and consistent assessment of transition outcomes are also 
urgently needed. It is for this reason that a bespoke suite 
of measures, focusing on transition of young people from 
CAMHS to AHMS, was developed within the EU- funded 
Managing the Link and Strengthening Transition from 
Child to Adult Mental Healthcare in Europe (MILE-
STONE) study.23 The MILESTONE suite of measures 
comprises the Transition Readiness and Appropriate-
ness Measure (TRAM), for assessing whether transition 
is appropriate for any young person who is approaching 
their transfer boundary in CAMHS, and whether they are 
ready for it, and the Transition Related Outcome Measure 
(TROM), which evaluates the outcomes of transition. The 
TRAM is currently being used within the MILESTONE 
cluster randomised controlled trial as one of the compo-
nents of the MILESTONE study23 to inform ‘Managed 
transition’ in the intervention arm. The present paper 
presents the findings on the validation of the TRAM.
MethODs
The methods linked with the development and validation 
of the TRAM have been described previously.24 Figure 1 
summarises the main stages, methods and analyses; only 
the key points are mentioned here. The US FDA Guid-
ance for Patient- reported Outcome Measures (PROM) 
was followed25 by beginning with a literature review on 
transitioning, which was followed by an expert panel 
review, a focus group phase measure consisting of devel-
opment and translation (so that the testing of the web- 
based versions could take place in the eight EU countries 
participating in the MILESTONE study),23 and finally a 
two- phase process. The first phase (MILESTONE vali-
dation study) involved 100 adolescents (pre- transition), 
young adults (post- transition), parents/carers and both 
CAMHS and AMHS clinicians and assessed content 
validity, construct validity and test–retest reliability. 
Participants completed the TRAM plus other existing 
measures (figure 1). The second phase involved over 
1000 young people as part of the MILESTONE cohort 
study and nested cluster randomised trial and assessed 
the responsiveness and interpretability of the TRAM and 
the psychometric properties (apart from test–retest). All 
study participants gave informed consent as per study 
guidelines. A complete list of all the ethics committees 
that provided ethical approval are provided in online 
supplementary information table 1. Data collection was 
part of the MILESTONE study, which has been described 
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Figure 1 Summary of the main stages, methods and analyses of the TRAM. AD, adolescent; AMHS, adult mental health 
services; CAMHS, child and adolescent mental health services; CL, clinician; PC, parent/carer; TRAM, Transition Readiness and 
Appropriateness Measure.
elsewhere alongside a detailed summary of the measures 
that were completed by participants and subsequently 
used in the validation of the TRAM.23
Internal consistency of the TRAM was calculated 
by means of the Cronbach’s alpha (α). The Pearson’s 
product moment correlation between three existing 
measures (Health of the Nation Outcome Scale for Chil-
dren and Adolescents (HoNOSCA)26 27 scale, Clinical 
Global Impression Severity (CGI- S)28 scale and Specific 
Levels of Functioning (SLOF) scale)29 and the new rating 
scales was calculated to assess whether the scores of the 
TRAM are related to scores on other instruments. Factor 
analysis was conducted to determine the underlying struc-
ture of the TRAM subscales and to identify patterns and 
characteristics of the factors. Results of the second phase 
of validation will also be used to inform modifications to 
the scale, in particular to improve the utility and accessi-
bility of the measure and minimise completion burden.
To assess whether the demographic characteristics were 
related to the TRAM subscales, we estimated the depriva-
tion index. The deprivation index was developed based 
on comparable variables present in the Jarman Index 
that is a widely used indicator for social deprivation.30 31 
In the context of the present study, the variables of the 
deprivation index were captured using the sociodemo-
graphic variables in the Sociodemographic Interview for 
the Parent. The following variables were used to estimate 
the deprivation index: (a) employment of parents versus 
unemployed, (b) if the young person was attending 
school or not, (c) lone parent, (d) ethnic minority, (e) 
parental history of mental illness, (f) socioeconomic 
factors, that is, receiving state financial support and (g) 
level of parental education.
Patient and public involvement
 ► Patients were involved in the development of the 
TRAM by taking part in focus groups and to discuss 
important themes to be assessed by the TRAM, and by 
piloting the initial versions of the measure.
 ► Young project advisors were involved in the project 
to see how it could be implemented and how the 
changes could be adopted by current mental health 
transition services.
results
Development of the trAM
Literature review
The detailed review of current literature and measures 
on transition in both mental and physical health resulted 
in a list of 64 items of potential importance, grouped into 
three main domains—diagnosis, risk and functioning—
forming the core structure of the TRAM.
Expert panel
It was decided that the TRAM should include questions 
on potential barriers to a successful transition (eg, young 
people not being able to act independently, not being 
motivated to manage their conditions or not under-
standing their conditions), as these reflect the young 
persons’ readiness for and functioning related to tran-
sition. Furthermore, it was hoped that addressing such 
issues within the TRAM would emphasise the need for 
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CAMHS and AMHS to work together before and/or 
during transition. The TRAM also considered the young 
person’s desired level of parental involvement, the ease 
with which they formed clinical relationships and whether 
they were able to discuss their mental health history. 
These elements were also deemed relevant for services to 
understand to avoid difficult or tricky situations that may 
potentially derail transition.
Focus groups
Focus groups were held with young people with experi-
ence of CAMHS and transition to AMHS (if applicable), 
parents and carers, CAMHS professionals and AMHS 
professionals. During the focus group discussions, young 
people voiced that ‘life events’ should be taken into 
account when deciding about transition. A large number 
of recent life events was thought to suggest a greater need 
for AMHS. These raise some important points that need 
to be considered during transfer when developing readi-
ness measures. Health transitions are only one of several 
life transitions during adolescence and young adulthood. 
Other factors also need to be taken into account during 
the transition period such as those relating to educational 
and social transitions including moving from parental 
home to independent living. Participants in the focus 
groups also identified the level of external support as 
being an important consideration when making transi-
tion plans, as those with less external support may have 
a greater need for continued statutory services. Young 
people, parents and CAMHS clinicians ranked social 
support and housing as important more often than the 
expert panel or AMHS clinicians. Poor engagement with 
tasks, lack of meaningful occupation and cognitive factors 
were considered the least important factors to consider 
when making a transition decision by all categories of 
participants. Questions relating to these issues were 
therefore removed from subsequent versions of the scale.
Organisation of items within subscales
Once the final list of items had been decided, the organ-
isation of these items was discussed with further focus 
groups and the MILESTONE expert panel. Based on this 
feedback, the preliminary version of the TRAM included 
domains A–F, which capture the ‘appropriateness’ of 
transition, and G and H, which capture ‘readiness’ for 
transition, as follows:
(A) Symptoms
Frequency and severity of symptoms to include depres-
sion, mania, anxiety, post- traumatic stress, psychosis, 
personality disorder, antisocial personality disorder, atten-
tion deficit, social communication, eating difficulties and 
other mental health conditions.
(B) Overall illness
This considered severity, taking into account all symp-
toms across all existing conditions.
(C) Overall disruption
Effect of symptoms on functioning with respect to 
self- care, sleep, household chores, community, social, 
responsibility, relationships with family, friends/partner, 
peers/colleagues and education/work performance.
(D) Risk factors
Frequency and severity of stress, risk- taking behaviour, self- 
harm (no suicidal intent), suicidal thoughts, behaviours 
that risk harm to others and behaviours that risk harm 
from others.
(E) Factors affecting symptoms
Including need for ongoing treatment, inpatient admis-
sions, relapse, side effects to medication, physical health 
comorbidities and drug and alcohol abuse.
(F) Health system factors
The health system factors that may affect a clinicians' 
transition decision include items such as financial impli-
cations of a transition to AMHS, the quality of the links 
between CAMHS and AMHS, the appropriateness of 
available statutory services, the availability of alternative 
services and the skills of local GPs with regard to mental 
health when treating a young person’s condition.
(G) Barriers to functioning
Including inability to act independently, poor under-
standing of condition, lack of knowledge on how to 
access services, lack of motivation, poor adherence to 
medication, lack of social support, not wanting carers 
to be involved, difficulty forming relationships with 
treatment team and difficulty repeating mental health 
history.
(H) Other life changes
Other life changes (positive or negative) relating to family 
relationships, relationships with friends and partner, 
moving home, school/college/work, illness/death, 
police involvement, pregnancy and other.
Both the frequency of symptoms and the severity of 
impairment (A (symptoms) and D (risk)) were assessed, 
as advised by focus groups participants. Again, following 
participant feedback, the severity of each symptom was 
recorded separately but a single assessment of impairment 
was made across all symptoms and conditions. Focus group 
participants also considered which options for assessing 
frequency and severity would be most appropriate. For 
frequency, the most popular choice was a 6- point ordinal 
scale (from not experienced in the past 6 months ranging 
to all of the time) and for severity, a 5- point ordinal scale 
(from very mild ranging to very severe). Unduly convo-
luted medical language was removed, and participants 
reported no major issues with completion of the scale. 
Experts in the field were asked to review the proposed 
scale. The agreed test version was translated into Croa-
tian, Dutch, French, German and Italian using a back- 
translation process32 and, after final checks, uploaded on 
the HealthTracker system, a web- based portal for online 
measures.
Validation of the trAM
In the first phase, the three versions of the TRAM were 
completed by a total of 36 adolescents (AD), 29 parents/
carers (PC) and 35 clinicians (CL), respectively.
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Table 1 Test–retest reliability of the TRAM (n=100)
Subscale
Adolescent Parent/Carer Clinician
(AD: n=36) (PC: n=29) (CL: n=35)
(A) Pearson’s correlation coefficients
  Symptoms 0.928** 0.936** 0.773**
  Overall 
disruption
0.817** 0.935** 0.942**
  Barriers to 
functioning
0.813** 0.908** 0.824**
  Risk factors 0.897** 0.864** 0.914**
  Factors 
affecting 
symptoms
0.734** 0.679** 0.912**
(B) Mean and SD
Baseline Test–retest Baseline Test–retest Baseline Test–retest
Symptoms
  Mean 16.667 14.167 12.379 10.466 11.629 11.300
  SD 9.789 9.667 8.548 8.757 5.945 6.253
Overall disruption
  Mean 9.944 8.694 8.655 8.379 11.086 11.200
  SD 6.697 5.956 8.784 8.954 7.625 8.554
Barriers to functioning
  Mean 7.472 6.778 6.655 6.034 7.086 6.314
  SD 3.501 3.743 4.685 3.530 3.673 3.636
Risk factors
  Mean 6.847 6.167 4.621 4.379 5.829 6.014
  SD 4.657 4.623 4.037 4.212 4.711 4.999
Factors affecting symptoms
  Mean 2.167 1.889 1.759 1.276 2.171 2.029
  SD 1.464 1.348 1.596 1.251 1.445 1.224
**p<0.01.
AD, adolescent; CL, clinician; PC, parent/carer; SD, standard deviation; TRAM, Transition Readiness and Appropriateness Measure.
In the main MILESTONE study (second phase), the 
TRAM was completed by a total of 932 AD, 752 PC and 
849 CL.
First phase
Test–retest reliability
In order to assess test–retest reliability, Pearson’s correlation 
coefficients were calculated between responses per the first 
and subsequent completion (a maximum of 41 days after 
the first assessment) for each subscale and version (AD, 
PC, CL) of TRAM. There were 36 AD, 29 PC and 35 CL 
completed TRAM’s available for the test–retest reliability 
analysis. The results are summarised in table 1(A),(B). 
There was moderate (>0.5) correlation33 between test–
retest scores for all versions (AD, PC, CL) and all subscales.
Second phase
Demographics for the AD, PC and CL sample are presented 
in online supplementary tables 2,3. The psychometric 
properties of the AD, PC and CL versions of the TRAM 
and all subscales for the larger sample are described in 
the ‘Internal consistency (reliability)’ section.
Internal consistency (reliability)
Cronbach’s α was calculated for all versions of the TRAM 
(AD, PC and CL versions) for the following subscales: 
symptoms, overall disruption, barriers to functioning, 
risk factors and factors affecting symptoms. Alpha ≥0.70 
is considered acceptable evidence of internal reliability.34 
The consistency of responses between versions (AD, PC 
and CL) was assessed using Pearson’s correlation coeffi-
cient. The internal consistency of the symptoms subscale 
was shown to be high for the AD version (α=0.804), 
acceptable for the PC version (α=0.759) and moderate for 
the CL version (α=0.552). The AD version for symptoms 
moderately correlated with the PC and CL version of the 
symptom subscale (r=0.517, p<0.01 and r=0.396, p<0.01, 
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Table 2 Pearson’s product moment correlation coefficients for the TRAM subscales with HoNOSCA and CGI- S scales
TRAM subscales
Scales Symptom Overall disruption Risk factors
Factors affecting 
symptoms
Barriers to 
functioning
HoNOSCA AD 0.378** (n=914) 0.345** (n=914) 0.370** (n=914) 0.306** (n=914) 0.249** (n=577)
HoNOSCA PC 0.369** (n=738) 0.329** (n=738) 0.374** (n=738) 0.349** (n=738) 0.151** (n=477)
HoNOSCA CL 0.478** (n=845) 0.437** (n=845) 0.442** (n=845) 0.357** (n=845) 0.340** (n=502)
CGI- S AD 0.242** (n=832) 0.261** (n=832) 0.210** (n=832) 0.294** (n=832) 0.149** (n=527)
CGI- S PC 0.319** (n=684) 0.285** (n=684) 0.237** (n=684) 0.338** (n=684) 0.187** (n=444)
CGI- S CL 0.548** (n=836) 0.514** (n=836) 0.373** (n=836) 0.352** (n=182) 0.307** (n=499)
**p<0.01; null hypothesis is that the Pearson’s correlation coefficient equals zero.
AD, adolescent; CGI- S, Clinical Global Impression Severity; CL, clinician; HoNOSCA, Health of the Nation Outcome Scale for Children and 
Adolescents; PC, parent/carer; TRAM, Transition Readiness and Appropriateness Measure.
respectively). Additionally, the PC version and CL version 
of the symptom subscale also revealed a moderate correla-
tion (r=0.393, p<0.01). The overall disruption subscale 
demonstrated high levels of internal consistency for all 
versions of the scale (AD version, α=0.869; PC version, 
α=0.882, CL version, α=0.877). The AD version for overall 
disruptions correlated with the PC and CL version of the 
overall disruption subscale (r=0.420, p<0.01 and r=0.380, 
p<0.01, respectively). Furthermore, the PC version and 
CL version of the overall disruption subscale also revealed 
a moderate correlation (r=0.505, p<0.01).
The barriers to functioning subscale scored adequate 
reliability for the PC and CL versions (α=0.725 and 0.714, 
respectively) with the AD version demonstrating slightly 
lower consistency (α=0.616). The AD version for barriers 
to functioning subscale moderately correlated with the 
PC and CL version of the overall disruption subscale 
(r=0.327, p<0.01 and r=0.401, p<0.01, respectively). 
Furthermore, the PC and CL version of the barriers to 
functioning subscale also revealed a moderate correla-
tion (r=0.380, p<0.01).
The risk factors subscale achieved adequate levels of 
internal consistency for the AD version (α=0.735), with 
the PC and CL versions revealing slightly lower consis-
tency (α=0.654 and 0.684, respectively). Once again, 
the AD version for risk moderately correlated with the 
PC and CL version of the risk subscale (r=0.552, p<0.01 
and r=0.557, p<0.01, respectively). Similarly, the PC 
version and CL version of the risk subscale also revealed a 
moderate correlation (r=0.529, p<0.01).
The factors affecting symptoms subscale did not exceed 
a Cronbach’s α of 0.70 for all versions (AD version 
α=0.554, PC version α=0.565, CL version α=0.522), with 
the AD version of the factors affecting symptoms subscale 
moderately correlating with the PC and CL version 
(r=0.610, p<0.01 and r=0.389, p<0.01, respectively). This 
relationship was also seen for the PC and CL versions of 
the factors affecting symptoms subscale (r=0.452, p<0.01).
The performance of the symptoms subscale for CL 
and the factors affecting symptoms subscale for AD, PC 
and CL fell below the minimum acceptable threshold. 
We therefore explored whether deletion of particular 
items might improve this and found that by removing the 
item relating to ‘attention deficit’ from the CL symptoms 
subscale, it would increase to 0.587. We also found that 
by removing the item about ‘medical comorbidity’ from 
the factors affecting symptoms subscale (AD, PC, CL), 
reliability would increase to 0.573 for the AD, 0.593 for 
the PC and 0.548 for the CL. Consequently, they were 
retained in the TRAM.
Correlations with other existing measures
To assess whether the TRAM could conceptually overlap 
with other existing instruments also completed by MILE-
STONE participants, the Pearson’s product moment 
correlation coefficient was calculated between each 
TRAM subscale and the gold standard HoNOSCA26 27 and 
the CGI- S28 (table 2). The Pearson’s product moment 
correlation coefficients for the TRAM subscales with 
HoNOSCA and CGI scales showed moderate correlations. 
Apart from the CGI (clinician version) for the symptoms 
and overall disruption, the correlation coefficients were 
all low (<0.500) suggesting a modest relationship between 
the TRAM subscale and HoNOSCA and CGI- S scores.
Pearson’s correlations were also determined between 
each TRAM subscale and the parent version of a 
behavioural rating scale: SLOF. The SLOF allows the 
capture of symptomatology using observable behavioural 
function in those with psychiatric illness.29 The subscale 
scores of the TRAM were analysed to see how well they 
correlate with the SLOF scale (AD, PC and CL) (table 3). 
The Pearson’s correlation between the TRAM subscales 
and SLOF subscales showed moderate associations. 
However, while the HoNOSCA and CGI showed signifi-
cant correlations with the TRAM scales, albeit moderate 
relationships, the SLOF scale revealed poor relationships 
(non- significant correlations) between some constructs 
measured by the former two scales.
Exploratory factor analysis
Exploratory factor analysis (EFA) (principal axis, promax 
rotation) was undertaken to model the inter- relationships 
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between the items in the TRAM and was performed on 
the adolescent version of the TRAM’s subscales. The 
TRAM was developed to assess whether transition is 
appropriate and whether the young person is ready for 
it. Based on this premise, the adolescent version of the 
scale was chosen as it was deemed to be the most rele-
vant version clinically to explore the inter- relationship 
between the items.
The first set of EFAs was performed without a set number 
of factors, these analyses showed that for ‘symptoms’ and 
‘factors affecting symptoms’ subscales a two factors model 
in line with the clinical knowledge can explain the rela-
tionship between the items of the subscales (see table 4 
for the details of the factors). These analyses, however, 
did not produce meaningful models for the ‘overall 
disruption’, ‘risk factors’ and the ‘barriers to functioning’ 
subscales. Therefore, another set of EFAs were performed 
where the number of factors were set on two for the 
‘overall disruption’, ‘risk factors’ and three for ‘barriers 
to functioning’ subscales. These EFAs returned for all the 
three subscales models which satisfy both statistical and 
clinical criteria. In the ‘barriers to functioning’ subscale, 
the three factors were identified based on clinical knowl-
edge of barriers that might impede functioning such as 
‘patient factors’, ‘family support’ and ‘treatment’. Table 4 
summarises the results of EFAs for the TRAM subscales. 
For all the subscales and the items were clustered based 
on clinical relevance.
Deprivation index
An approximate measure of deprivation was estimated 
by creating the deprivation index. The deprivation index 
correlations with the overall TRAM subscale scores in the 
AD, PC and CL version are shown in table 5. The depri-
vation index correlated significantly with the AD, PC and 
CL versions of the overall disruption subscale. Pearson’s 
correlations were significant for the PC and CL version 
but not the AD version of the 'symptoms' and 'risk factors' 
subscale.
DIsCussIOn
This current manuscript reports on the development and 
validation of the TRAM. The TRAM was designed and 
worded specifically so that it can be completed online, 
optimising both completion time and accessibility; thus, 
increasing its potential applicability in an adolescent/
young adult population. The benefit of following the 
rigorous FDA process while developing TRAM was that 
feedback on potential items was gained early on from end 
users. Importantly, items such as diagnosis, risk and func-
tioning were identified as important items in the transi-
tion decision- making process. The psychometric analyses 
revealed that the TRAM is a reliable and valid instrument 
for assessing transition. The TRAM had good reliability 
for all versions and showed moderate- to- low correlations 
when pitted with other established instruments. This 
finding supports the use of TRAM to assess transition 
readiness, as higher correlations would imply that the 
TRAM was not adding anything new when compared with 
existing measures such as HoNOSCA. The goal of the 
TRAM to assess readiness and appropriateness were met 
because the TRAM was holistic in its scope to explore the 
key items that captured the overarching themes relating 
to transition readiness and appropriateness.
When looking more closely at the correlations of the 
TRAM, there were conceptual differences between the 
TRAM subscales and existing instruments. Regarding 
the HoNOSCA, the Pearson’s correlations were all below 
0.500 for the different versions suggesting a modest rela-
tionship between the HoNOSCA total score and TRAM 
subscale scores. Previous studies that have assessed the 
correlations between the HoNOSCA total score and other 
instruments such as the parent and clinician rated Chil-
dren's Global Assessment Scale35 and the Global Assess-
ment of Psychosocial Disability36 have reported moderate 
correlations ranging from 0.4 to 0.6. The present 
study also reported modest correlations between the 
TRAM subscale and HoNOSCA total scores suggesting 
that conceptually the instruments measure different 
elements of transition. A similar reasoning can be put 
forward when examining the TRAMs performance with 
the CGI. The CGI considers aspects of three different 
global measures (i) severity of illness (CGI- S), (ii) global 
improvement and (iii) efficacy index.28 In the context 
of this study, the CGI- S was considered and embodies all 
the aspects regarding the overall severity of symptoms of 
the young person into a single score. In comparison, the 
TRAM subscales are more specific. The subscales of the 
SLOF make it conceptually closer to the TRAM in terms 
of looking at the functioning aspects of transition when 
compared with the HoNOSCA or CGI- S. Although there 
was not a complete overlap, it was easier to classify indi-
vidual correlations based on their meaningfulness. As 
expected, there were poor correlations (not significant) 
that can be explained by a conceptual difference between 
the construct measured by SLOF (that does not specifi-
cally focus on transition readiness) and TRAM subscales.
From a clinical viewpoint, the EFA for the adolescent 
version showed that a two factors model was the most 
suitable for the ‘symptoms’, ‘overall disruption’, ‘risk 
factors’ and ‘factors affecting symptoms’ TRAM subscale. 
The items were grouped together based on clinical judge-
ment, for example, in the ‘symptoms’ subscale the items 
anxiety and depression were grouped together in factor 
one while antisocial behaviour and mania were catego-
rised together in factor 2. In some instances, however, 
some items had lower loading values. The item ‘other 
mental health’ had a loading score of 0.186 in the ‘symp-
toms’ subscale suggesting a weaker association in compar-
ison to the other items in this subscale. There is, however, 
no rule of thumb regarding the optimal strength of factor 
loadings and thresholds. Indeed, one meta- analysis of the 
variance in factor loading has shown that there is no agree-
ment to what constituents a high or low factor loading.37 
The items anxiety and depression clustered together with 
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Table 4 Summary of EFA for the adolescent version of the TRAM’s subscales
Factors
Internalising symptoms Externalising symptoms
Symptoms subscale
  Anxiety 0.896 −0.222
  Depression 0.794 0.020
  Borderline personality 0.482 0.334
  Post- traumatic stress 0.358 0.197
  Social communication difficulties 0.356 0.196
  Eating difficulties 0.313 0.086
  Other mental health 0.186 0.107
  Antisocial behaviour −0.083 0.585
  Mania −0.019 0.570
  Attention deficit 0.139 0.380
  Psychosis 0.282 0.366
Relationships Activities of daily living
Overall disruption subscale
  Relationships with friends 0.903 −0.088
  Relationships with peers/colleagues 0.845 −0.082
  Social 0.550 0.199
  Relationships with family 0.455 0.124
  Education work performance 0.406 0.256
  Sleep 0.360 0.244
  Household chores 0.017 0.721
  Self- care −0.059 0.708
  Responsibility 0.048 0.678
  Community 0.252 0.432
Patient factors Family support Treatment
Barriers to functioning subscale
  Knowledge of accessing service 0.636 −0.103 −0.053
  Ability to act as independent 0.591 −0.232 0.031
  Understanding of mental health 0.496 0.055 −0.061
  Adolescent built trusting relationship 0.420 0.225 0.011
  Ability to repeat history 0.413 0.230 −0.087
  Adolescent wants parent carer −0.078 0.691 −0.100
  Presence of support 0.031 0.527 0.141
  Taking medication as prescribed −0.149 −0.052 0.529
  Motivation to manage condition 0.172 0.081 0.496
Internal risk External risk
Risk factors subscale
  Suicidal thoughts behaviours 0.848 0.001
  Self- harming behaviours 0.788 −0.056
  Stress 0.397 0.130
  Risk to others −0.073 0.649
  Risk to self 0.145 0.529
  Risk from others 0.234 0.269
Relapse of illness factor Somatic illness factor
Continued
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Factors affecting symptoms subscale
  Inpatient hospital stays 0.594 −0.088
  Service use in times of crisis 0.569 −0.037
  Relapse likelihood 0.477 0.145
  Ongoing treatment need 0.365 0.146
  Drug alcohol misuse 0.363 −0.110
  Presence of side effects −0.041 0.461
  Medical comorbidity −0.039 0.335
The values in bold represent the highest loading in a factor for each item of the subscale. The threshold of acceptance was set at >0.150.
EFA, exploratory factor analysis; TRAM, Transition Readiness and Appropriateness Measure.
Table 4 Continued
Table 5 Summary of deprivation index correlations with 
TRAM subscales
Deprivation index correlations
AD PC CL
Symptoms subscale
  Pearson’s 
correlation
0.027 0.116** 0.089*
  Sig. (two- tailed) 0.454 0.002 0.017
  N 768 732 719
Risk factors subscale
  Pearson’s 
correlation
0.052 0.175** 0.118**
  Sig. (two- tailed) 0.148 0.000 0.001
  N 768 732 719
Overall disruption subscale
  Pearson’s 
correlation
0.083* 0.162** 0.127**
  Sig. (two- tailed) 0.021 0.000 0.001
  N 768 732 719
Factors affecting symptoms subscale
  Pearson’s 
correlation
0.031 0.111** 0.085
  Sig. (two- tailed) 0.396 0.003 0.298
  N 768 732 151
Barriers to functioning subscale
  Pearson’s 
correlation
−0.046 0.061 −0.019
  Sig. (two- tailed) 0.301 0.181 0.699
  N 500 477 435
*p<0.05, **p<0.01; null hypothesis is that the Pearson’s correlation 
coefficient equals zero.
AD, adolescent; CL, clinician; PC, parent/carer; TRAM, Transition 
Readiness and Appropriateness Measure.
factor loading scores >0.7 reflecting a higher degree of 
impact these items have when a young person prepares 
for transition. Similarly, in the ‘risk factors’ subscale the 
items ‘suicidal thoughts behaviours’ and ‘self- harming 
behaviours’ had the highest factor loading scores in 
comparison to the other items indicating that when it 
comes to risk and how it impacts on the preparedness 
of when a young person’s transition, suicidal thoughts 
and self- harming behaviours are two elements that can 
have a significant impact on how a young person navi-
gates transition. The barriers to functioning subscale 
revealed a three- factor model. On closer examination, 
while five items clustered together in factor 1, the item 
‘knowledge of accessing services’ had the highest factor 
loading score in this factor. Interestingly, this score was 
higher than the ‘ability to act independently’ score. This 
observation suggests that when it comes to examine the 
barriers of transition, knowledge of accessing services are 
more important than whether the young person has the 
ability to act independently or understands the degree 
of how the severity of their mental illness will impact on 
the transition process. This point is echoed in the liter-
ature and supports the overarching theme voiced by 
young people and others that transition from CAMHS to 
AMHS should be individualised and be flexible enough 
to manage the obstacles encountered during the transi-
tion process.17 21 22 38 Despite this, the ability to act inde-
pendently should not be understated. Young people will 
have different developmental milestones during their 
transition journey. This is particularly important during 
the latter stages of transition which often takes place in 
young adulthood as the brain is still developing. From a 
neurodevelopmental perspective, this point should not 
be taken lightly by services who sometimes forget that 
even at this stage of the transition process they are dealing 
with developing young people. Overall, these findings 
showed that the items could be mapped onto readiness 
and appropriateness. This will form the basis of a transi-
tion passport that will assist in the identification of high- 
risk cases or those who can be appropriately discharged 
or transitioned to another community service. The transi-
tion passport will be described elsewhere.
The study was able to estimate a deprivation index based 
on sociodemographic variables captured as part of the 
MILESTONE study and showed a significant relationship 
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with the ‘overall disruption subscale’ in all versions of the 
scale, and the parent and clinician version of the ‘symp-
toms’ and ‘risk factors’ subscale. This is not surprising as 
these subscales have items grouped according to relation-
ships, internalising/externalising symptoms and risk and 
these factors would be related to the sociodemographic 
aspects assessed using the deprivation index. While there 
are several indices that can be used for outcome services, 
the Jarman Index can be used as a proxy for deprivation 
and while some evidence has shown that it might not be 
entirely suited to the planning of healthcare outcomes,39 
we have used elements of it to estimate a deprivation 
index that showed significant inter- relationships with 
TRAM subscales.
strengths and limitations
The TRAM has a dual purpose: to identify who should 
be transitioned to adult mental health services and to 
pinpoint areas which should be considered or addressed 
to ensure that the transition process is smooth. The 
barriers to a successful transition are areas which clini-
cians on both sides of the transfer boundary can work 
on to improve the ease of transition. These barriers 
include young people not being ready to act as an inde-
pendent adult; young people not understanding their 
mental health condition or not being motivated to 
manage their condition; not having social support, not 
easily building therapeutic relationships and not easily 
being able to repeat history. The TRAM score summary 
report contains the TRAM responses of the AD, PC and 
CL, presented in visually attractive graphs and tables and 
serves as a clinician decision support tool and commu-
nication aid. Yellow highlights help clinicians focus on 
items requiring attention. If a referral to adult services 
seems appropriate for the young person but barriers are 
highlighted, the clinician can add these to the care plan 
and address them in a timely fashion to help smoothen 
the transition process. Moving forward, based on the 
TRAM validation study findings, a MILESTONE Transi-
tion Predictor will be developed on the HealthTracker 
platform, to be used in association with the TROM. As 
transition is dependent on symptoms clusters, the transi-
tion predictor will be able to provide a personalised tran-
sition approach depending on symptom profiling. This 
will involve using a traffic light scoring system to a modi-
fied TRAM score summary report to predict the outcome 
of transition based on symptom profiling. Together with 
the TROM, these clinical decision- making tools will be 
valuable in identifying cases who need to transition based 
on symptomatology and then to assess the outcomes of 
the transition process. Young person’s undergoing transi-
tion present with complex psychopathology and as such 
those participants who were the most severely ill or less 
engaged with the transition process are least likely to have 
responded. Notwithstanding these concerns, the measure 
is still likely to be useful in these high- risk groups and 
would be beneficial for healthcare practitioners. Despite 
the focus groups not having patients who were very ill, 
the validation was done in a mixed group of patients 
with multiple disorders of varying complexity and hence 
shows that the TRAM can be used in complex psychopa-
thology. The present study was also unable to assess tran-
sition readiness and how it can evolve over across time. 
This would be important given that young people are 
likely to have several transitions during their transition 
journey and although the TRAM did not capture transi-
tion from other services ie, within social care, it could still 
be used as a foundation to develop similar measures for 
other services. Future work would need to explore transi-
tion readiness in young people during their entire tran-
sition journey and the usefulness of TRAM across other 
age- based services.
COnClusIOn
The current study suggests that the TRAM is a viable instru-
ment for determining the readiness of a young person 
and the appropriateness for transition from CAMHS. It 
is holistic in its scope to ensure that the young person 
is seen as more than a list of symptoms and assessment 
involves not only clinicians but also young people and 
their parents/carers. Being web- based allows the measure 
to be used across countries by end users and enriches the 
transition process from CAMHS to AMHS. This means 
that the TRAM has the potential to be used worldwide by 
end users, thereby contributing to a smoother transition 
process and allowing for personalised mental healthcare. 
Ultimately, this will have added value in informing the 
transition process from CAMHS to AMHS. The TRAM is 
designed to work in conjunction with an instrument that 
examines the outcome of transition.
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